Beyond Heart Attack: A New Lens on Risk

Key Takeaway: The American Heart Association’s new PREVENT equations represent a fundamental shift in cardiovascular risk prediction. These equations move beyond just heart attacks and strokes to focus on predicting heart failure risk, incorporating kidney function and metabolic health into the process. By calculating the expected benefit of treatment in absolute terms, these equations provide a concrete figure for physicians and patients to use as a basis for discussing the decision to start a new medication.

A Long-Awaited Advancement in Risk Calculation

For nearly a decade, the cornerstone of cardiovascular prevention in the United States has been the “Pooled Cohort Equations.” These formulas estimated the ten-year risk for atherosclerotic cardiovascular disease (ASCVD), namely heart attack and stroke. While they transformed clinical practice upon their release in 2013, these equations were a product of a different era^[2]. They were based on data from cohorts established decades ago, did not fully reflect the country’s diversity, and overlooked two of the most powerful drivers of modern cardiovascular problems: chronic kidney disease and metabolic disorders like obesity and type 2 diabetes. Now, a new AHA/ACC Scientific Statement provides a practical roadmap for implementing their successor: the PREVENT equations. These new equations were designed from the ground up for the modern epidemic of intertwined cardiovascular, kidney, and metabolic (CKM) diseases^[1].

Recommendations from the Scientific Statement

This statement is not the result of a single clinical trial. It is an expert consensus document—a detailed, evidence-based roadmap explaining how physicians should use the PREVENT equations in daily practice. The equations themselves were developed using data from more than 6.6 million adults across diverse community cohorts, making them far more representative of today’s U.S. population than their predecessors^[3].

Several features distinguish this new framework. First, PREVENT does more than just predict ASCVD. It generates outcome-specific risk estimates for total cardiovascular disease, atherosclerotic events (heart attack and stroke), and, crucially, heart failure. Heart failure affects more than six million Americans and has long been the “orphan child” of primary prevention; unlike with heart attacks, there was no validated tool to quantify a patient’s risk of developing heart failure^[4]. PREVENT fills this gap.

Second, the equations incorporate kidney function (estimated glomerular filtration rate or eGFR) and metabolic markers not as afterthoughts, but as fundamental inputs. This is critical because chronic kidney disease roughly doubles the risk of cardiovascular mortality, and metabolic syndrome creates a smoldering inflammatory state that accelerates atherosclerosis and myocardial stiffening^[5]. Ignoring these factors was akin to forecasting a hurricane without considering the ocean temperature.

Third, and perhaps most transformative, the statement recommends using PREVENT not just to label a patient as “high-risk” or “low-risk,” but to calculate the expected benefit of a specific therapy. This means estimating the absolute risk reduction a patient can expect from starting, for example, a statin or an antihypertensive medication. The shift from saying “Your risk is X percent” to “This medication can reduce your risk by Y percent over ten years” facilitates a fundamentally different conversation.

The PREVENT equations also offer clinicians a broader time horizon and personalized assessment tools. For individuals between the ages of 30 and 59, 30-year cardiovascular risk can also be calculated in addition to 10-year risk. Particularly in young adults whose short-term risk may appear low, calculating their “risk percentile for their age and sex group” can identify long-term danger early on.

The process is managed by the 4-step C-P-R (Calculate – Personalize – Reclassify – Shared Decision Making) framework introduced in the guideline:

1. Calculate: Quantitative risk is calculated with PREVENT.
2. Personalize: “Risk-enhancing factors” not included in the equation are considered, such as rheumatologic/inflammatory diseases, pregnancy complications (preeclampsia, gestational diabetes), premature menopause, sleep apnea, a family history of kidney failure, and socioeconomic conditions.
3. Reclassify: When necessary, risk is clarified with advanced biomarkers and imaging.
4. Shared Decision Making: A treatment plan is developed with the patient, weighing the benefit/cost balance.

The Body’s Systemic Nature: Beyond Organ Boundaries

The biological rationale behind PREVENT reflects a reality clinicians see every day: the heart, kidneys, and metabolic system are locked in a three-way feedback loop. When the kidneys fail, they cause sodium and fluid retention, raising blood pressure and stretching the heart’s chambers. High blood pressure, in turn, damages the delicate glomerular capillaries in the kidney, accelerating renal decline. Meanwhile, insulin resistance and visceral adiposity trigger chronic low-grade inflammation, endothelial dysfunction, and arterial stiffness—all of which create a vicious cycle that feeds both cardiac and renal damage^[6].

This is the essence of CKM syndrome, a staging framework the AHA introduced alongside the PREVENT equations. This framework acknowledges that cardiovascular disease doesn’t start the day a coronary artery becomes blocked. The disease begins years, or even decades, earlier with excess adiposity (Stage 1), metabolic risk factors like hypertension and dyslipidemia (Stage 2), subclinical organ damage (Stage 3), and finally, symptomatic cardiovascular disease (Stage 4)^[7]. By capturing kidney and metabolic inputs, PREVENT is calibrated to detect risk in these earlier, more modifiable stages.

The prediction of heart failure warrants special attention here. Unlike a heart attack, which is typically caused by the sudden rupture of plaque in a coronary artery, heart failure is often the slow-motion result of years of pressure overload, metabolic toxicity, and neurohormonal activation. The left ventricle thickens, stiffens, and eventually can no longer fill or pump blood efficiently. Traditional risk calculators focused on plaque events completely missed this trajectory. PREVENT’s inclusion of heart failure as a separate endpoint acknowledges that preventing a heart attack and preventing heart failure may require different strategies, and patients deserve to know their risk for both.

A critical turning point in CKM staging is Stage 3 (Subclinical Organ Damage), the phase where the disease has begun at the tissue level but has not yet produced symptoms. PREVENT establishes concrete screening thresholds to catch this silent stage:

• Pre-Heart Failure Screening: In individuals with a 10-year heart failure risk of 5% or higher on the PREVENT-HF calculation, checking cardiac biomarkers (NT-proBNP or hs-cTn/troponin) is recommended even without symptoms. If biomarkers are elevated, an echocardiogram is performed to examine the heart’s structure.
• Screening for Hidden Atherosclerosis: In patients with a PREVENT-ASCVD risk between 3% and 10% where the treatment decision is uncertain, a Coronary Artery Calcium (CAC) score can be measured to screen for hidden calcification and plaque burden.

Furthermore, a 10-year PREVENT-CVD risk of 20% or higher or the presence of advanced kidney damage is considered a Stage 3 (Subclinical Disease Equivalent), even if the patient has no known heart disease, and necessitates the initiation of the most aggressive preventive therapies.

What This Means for Your Next Medical Appointment

In practice, PREVENT is designed to guide two of the most common decisions in primary care: whether to start or intensify a blood pressure medication and whether to start or intensify a cholesterol-lowering therapy. The statement advises physicians to use these equations to estimate the absolute risk reduction—the tangible benefit—before recommending a new medication. This approach moves the dialogue from a fear-based framework (“you are at high risk”) to a benefit-based one (“let’s see how much this treatment can help you”).

For example, for a patient with early-stage kidney disease and prediabetes, PREVENT might reveal a much higher ten-year cardiovascular risk than the old Pooled Cohort Equations would have estimated, and consequently show a greater expected benefit from statin therapy. This kind of information can make the difference between a patient who fills their prescription and one who doesn’t.

The emphasis on shared decision-making is deliberate. A risk number alone doesn’t tell a patient what to do. But a risk number combined with an expected benefit—”Starting this medication could lower your chance of having a cardiovascular event in the next ten years from 18 percent to 12 percent”—gives both the physician and the patient a concrete foundation for weighing the benefits against side effects, costs, and personal preferences.

The greatest clinical revolution brought by PREVENT is its guidance not only for blood pressure and cholesterol medications but also for decisions to start next-generation cardioprotective drugs (GLP-1 receptor agonists and SGLT2 inhibitors).

According to the guideline, in a patient with Type 2 diabetes and Stage 2/3 CKM syndrome, if the 10-year PREVENT-CVD risk is 7.5% or higher, GLP-1 based therapies (e.g., semaglutide) or SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) should be incorporated into the treatment regimen to prevent heart attack, heart failure, and kidney damage. As a practical rule of thumb, almost all patients aged 50 and over with diabetes and an additional risk factor like hypertension will exceed this 7.5% treatment threshold.

An integral part of these check-ups is regular organ screening:

• Kidney Screening: All patients with Stage 2 CKM or higher should have their eGFR and urine albumin-to-creatinine ratio (uACR) checked at least annually.
• Liver and Sleep Screening: In those with diabetes or metabolic risk, the FIB-4 index should be calculated every 1-2 years to assess the risk of fatty liver disease and fibrosis; those with obesity should be screened annually for Obstructive Sleep Apnea.

Limitations to Consider

No risk calculator is a crystal ball. PREVENT was developed and validated with population-level data; individual patients will always have unique genetic, behavioral, and social factors that no equation can fully capture. The equations also rely on accurate input data; if kidney function or metabolic markers are not measured, the calculator cannot account for them. Moreover, while PREVENT is more inclusive than its predecessors, continuous validation in specific subpopulations, including young adults and those with rare metabolic conditions, will be essential as the tool gains wider adoption. A scientific statement, no matter how rigorous, represents expert consensus at a specific moment in time, and clinical practice will continue to evolve as real-world implementation data accumulates.

In addition to clinical limitations, economic realities are one of the biggest obstacles to this approach. As the guideline notes, the high cost of organ-protective next-generation drugs like GLP-1 therapies and SGLT2 inhibitors currently limits their widespread applicability at a societal and health system level. For these treatment protocols to be accessible to all patients equitably and fairly, price reductions and the availability of generic options will be necessary.

---

Scientific Sources

1. Khan SS, et al. Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2026;154(4):e159-e180. PubMed: https://pubmed.ncbi.nlm.nih.gov/42263147/
2. Goff DC Jr, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014. DOI: 10.1161/01.cir.0000437741.48606.98
3. Khan SS, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024. DOI: 10.1161/CIRCULATIONAHA.123.067626
4. Virani SS, et al. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation. 2021. DOI: 10.1161/CIR.0000000000000950
5. Go AS, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004. DOI: 10.1056/NEJMoa041031
6. Ronco C, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008. DOI: 10.1016/j.jacc.2008.07.051
7. Ndumele CE, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023. DOI: 10.1161/CIR.0000000000001184

Share this article

LinkedIn X Facebook WhatsApp Copy Link